Filtered By:
Condition: Depression
Cancer: Cancer
This page shows you your search results in order of date. This is page number 7.
Order by Relevance | Date
Total 564 results found since Jan 2013.
Cognitive impairment, anxiety and depression: a map of Cochrane evidence relevant to rehabilitation for people with post COVID-19 condition
CONCLUSIONS: These results are the first step of indirect evidence able to generate helpful hypotheses for clinical practice and future research. They served as the basis for the three recommendations on treatments for these PCC symptoms published in the current WHO Guidelines for clinical practice.PMID:36534008 | DOI:10.23736/S1973-9087.22.07813-3
Source: European Journal of Physical and Rehabilitation Medicine - December 19, 2022 Category: Rehabilitation Authors: Claudio Cordani Vanessa M Young Chiara Arienti Stefano G Lazzarini Matteo J Del Furia Stefano Negrini Carlotte Kiekens Source Type: research
IJERPH, Vol. 19, Pages 16741: 1000 Days: The & ldquo;WeCare Generation & rdquo; Program & mdash;The Ultimate Model for Improving Human Mental Health and Economics: The Study Protocol
Discussion: An overall rate of return on investment (ROI) statistically significant 13.0% per annum with an associated benefit/cost ratio (BCR) of 6.3 is expected as the primary outcome of the “WeCare Generation” program. Our proposed model predicts a new medical paradigm aiming to empower new generations, with a strong return on economy and health.
Source: International Journal of Environmental Research and Public Health - December 13, 2022 Category: Environmental Health Authors: Orlando Uccellini Andrea Benlodi Emanuele Caroppo Loredana Cena Gianluca Esposito Isabel Fernandez Maria Ghazanfar Antonio Imbasciati Francesco Longo Marianna Mazza Giuseppe Marano Renata Nacinovich Antonio Pignatto Arthur Rolnick Marco Trivelli Elena Spa Tags: Article Source Type: research
The final puff: Can New Zealand quit smoking for good?
Smoking kills. Ayesha Verrall has seen it up close. As a young resident physician in New Zealand’s public hospitals in the 2000s, Verrall watched smokers come into the emergency ward every night, struggling to breathe with their damaged lungs. Later, as an infectious disease specialist, she saw how smoking exacerbated illness in individuals diagnosed with tuberculosis and HIV/AIDS. She would tell them: “The best thing you can do to promote your health, other than take the pills, is to quit smoking.”
Verrall is still urging citizens to give up cigarettes—no longer just one by one, but by the thousands. As New...
Source: ScienceNOW - December 9, 2022 Category: Science Source Type: news
PCR225 Quality of Life (QOL)-Related Mentions for Prevalent Diseases on Social Media Platforms in the US
People discuss online the impact of health conditions on their lives. Comparing ‘posts’ across diseases may provide an initial understanding of comparative disease burden on quality of life (QOL). For 8 of the most prevalent conditions in the USA (ischemic heart disease [IHD], low back pain, chronic obstructive pulmonary disease [COPD], diabetes mellitus [DM], lung cancer, stroke, depression, migraine), we identified the number of posts focused on QOL, examined the main topics/words used with the QOL term, and explored the proportion of posts with “positive” and “negative” sentiments.
Source: Value in Health - December 1, 2022 Category: International Medicine & Public Health Authors: O Onwude, M Casamayor, T Saraykar, R Shome, M Reaney Source Type: research
Ischemic stroke of unclear aetiology: a case-by-case analysis and call for a multi-professional predictive, preventive and personalised approach
AbstractDue to the reactive medical approach applied to disease management, stroke has reached an epidemic scale worldwide. In 2019, the global stroke prevalence was 101.5 million people, wherefrom 77.2 million (about 76%) suffered from ischemic stroke; 20.7 and 8.4 million suffered from intracerebral and subarachnoid haemorrhage, respectively. Globally in the year 2019 — 3.3, 2.9 and 0.4 million individuals died of ischemic stroke, intracerebral and subarachnoid haemorrhage, respectively. During the last three decades, the absolute number of cases increased substantially. The current prevalence of stroke is 110 million ...
Source: EPMA Journal - November 17, 2022 Category: International Medicine & Public Health Source Type: research
Resiliency intervention for patient-caregiver dyads in the Neuro-ICU: Study protocol for a single-blind randomized clinical trial
DISCUSSION: If successful, we plan to test RT in a large-scale, multisite hybrid effectiveness-implementation study in Neuro-ICUs across the country. Enhancing psychosocial supports for patients and families could improve health outcomes, healthcare efficiency, and the culture of these units.PMID:36368480 | DOI:10.1016/j.cct.2022.106998
Source: Cancer Control - November 11, 2022 Category: Cancer & Oncology Authors: Ana-Maria Vranceanu Emily C Woodworth Millan R Kanaya Sarah Bannon Ryan A Mace Heena Manglani Brooke A Duarte Christina L Rush Nathaniel R Choukas Ellie A Briskin Joshua Cohen Robert Parker Eric Macklin Ethan Lester Lara Traeger Jonathan Rosand Karon M Ko Source Type: research
U.S. FDA Approves TECVAYLI ™ (teclistamab-cqyv), the First Bispecific T-cell Engager Antibody for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
HORSHAM, Pa., October 25, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) approved TECVAYLI™ (teclistamab-cqyv) for the treatment of adult patients with relapsed or refractory multiple myeloma, who previously received four or more prior lines of therapy, including a proteasome inhibitor, immunomodulatory drug and anti-CD38 monoclonal antibody.1 TECVAYLI™ is a first-in-class, bispecific T-cell engager antibody that is administered as a subcutaneous treatment.1 This off-the-shelf (or ready to use) therapy uses innovative science to ac...
Source: Johnson and Johnson - October 25, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
